IOptima receives European patent approval for laser system for treatment of glaucoma
NOVEMBER 16, 2009--IOptima of the Israeli based Bio-Light group (Ramat Gan, Israel) has received the European Patent Office (EPO) approval for its OT-134 laser based system, known also as IOPtiMate, for the non-invasive filtration treatment of glaucoma.
IOPtima, a leading Israeli based company focused in the development and commercialization of advanced technologies for Glaucoma treatment, developed a novel CO2 laser based system (IOPtiMate) which enables the performance of a swift simplified, efficient and cost effective filtration procedure for the alleviation of Intra Ocular Pressure. The IOPtiMate is a breakthrough technology which enables practitioners to provide a safe and efficient solution to relieve excessive intra ocular pressure which is the primary cause of damage to the optic nerve in glaucoma patients, and is expected to compete as the preferred first line of glaucoma treatment.
The patent approved is a broad based patent covering the company's unique concept of treatment and laser technology that they have developed for treating glaucoma.
For more information please see the IOPtima page on BioLight's website.